---
from: codex
to: all
status: done
created: 2026-05-31
next_action: "COO/CSRO: publish the missing activation/open-directives inputs or treat this synthesis as Codex's current queue seed."
---

# Codex Status Synthesis — 2026-05-31

## Inputs read

- `ops/policies/bot-coordination.md`
- `QC-STANDARDS.md` §1
- `ops/policies/bot-fleet.md`
- `ops/handoffs/2026-05-30-end-of-day-status.md`
- Current `main` log through `0db6986`

## Blockers routed around

- `ops/handoffs/2026-05-30-csro-fleet-activation.md` is not present on current `main`.
- `ops/csro/open-directives.md` is not present on current `main`.
- No `ops/csro/daily/` brief or drift-alarm files are present yet.

I did not idle on these missing inputs. I used the lane policy, bot-fleet map, EOD status, and current git log as the queue seed.

## Current Codex lane constraints

- Codex is read-only by default.
- Codex may write `codex/`-branch status synthesis or PR-review summary docs.
- Codex may make narrow QC-only fixes only when explicitly requested by COO or Carlo.
- Codex must not touch app code, content, config, or another bot's lane without explicit authorization.

## Ready queue

1. Produce chat-first PR-risk summaries for recent high-risk merges: Vets.co directory (#189), Reddit/data partnership surfaces (#190), therapeutic diet buy-boxes (#184), affiliate leak fix (#183), and Dog.com symptoms/compare surfaces (#182/#188).
2. Check whether prior draft IR findings are still valid on current `main`; report in chat only unless Carlo asks for filed handoffs.
3. Build a Codex PR-review summary template that stays inside the Codex lane and can be reused for high-risk PRs.
4. Monitor for the first CSRO daily brief and synthesize it with the last 24h of merges for Carlo's phone-summary path.
5. If `ops/csro/open-directives.md` appears, extract Codex-relevant items and convert them into a five-item active queue.

## Trust-bar reminder

QC §1 controls all review work: no fabricated authority, no fake testing, no fake schema reviewers, no invented superlatives, source-anchor clinical/statistical claims, and keep editorial standards pages truthful.
